<DOC>
	<DOCNO>NCT01208506</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetic ( effect body investigated drug ) , pharmacodynamic biomarkers ( biomarkers relate anti-IL-21 expect mode action ) sign clinical efficacy increase single dos , 9 i.v . ( vein ) dose level Healthy Subjects , 3 i.v . dose level subject rheumatoid arthritis ( RA ) 3 s.c. dose level Healthy Subjects .</brief_summary>
	<brief_title>First-in-Man Trial NNC114-0005 Healthy Subjects Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>For subject follow applies : Male subject , sterilize , must use two acceptable method contraception ( e.g. , spermicidal gel plus condom ) entire duration trial correspond three month follow trial drug administration . Male subject must also agree refrain sperm donation screening ( trial start ) 120 day beyond trial drug administration For healthy subject ( HS ) follow additional criterion applies : Male subject , age 18 60 year ( inclusive ) good health , determine past medical history , physical examination , vital sign , ( electrocardiogram ) ECG , laboratory test screen ( trial start ) For subject rheumatoid arthritis ( RA ) follow additional criterion applies : Diagnosed RA least 3 month prior trial drug administration Active RA , characterise Disease Activity Score 28 ( DAS28 ) Creactive protein ( CRP ) great 3.2 Effective method contraception Male female subject age great equal 18 great equal 75 year Females must postmenopausal surgically sterile ( postmenopausal least 1 year ) . If female childbearing potential must willing use highly effective method birth control trial final visit Methotrexate treatment ( MTX ) treatment least 12 week stable dose ( dose least 7.5 mg/week maximum 25 mg/week inclusive ) least 4 week prior trial product administration Concomitant medication accord specific list For subject follow applies : Body mass index ( BMI ) 20.038.0 kg/m2 ( inclusive ) Females positive pregnancy test History regular alcohol consumption exceed 14 drink per week female 21 drink per week men Donation loss least 400 mL blood within 8 week prior trial product administration For healthy subject ( HS ) follow additional criterion applies : Body weight great 110.0 kg For subject rheumatoid arthritis ( RA ) follow additional criterion applies : Chronic inflammatory autoimmune disease RA ( except secondary Sj√∂gren 's syndrome stable hypothyroidism ) History current inflammatory joint disease RA gout ( crystal proven ) , psoriatic arthritis , juvenile idiopathic arthritis , current reactive arthritis Lyme disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>